Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, VEGF and VUC in bladder cancer diagnosis

National Medical Journal of China

Volumn 85, Issue 35, 2005, Pages 2507-2512

  Sun, Yi ^a   He, Hui ^a   Ma, Qiang ^a   Wang, Xing Yang ^a   Yang, Lin ^a   He, Da Lin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Bladder neoplasms; Diagnosis; Tumor markers; Urine

Indexed keywords

CD44V6 ANTIGEN; NUCLEAR MATRIX PROTEIN 22; SURVIVIN; TUMOR MARKER; VASCULOTROPIN;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEASIBILITY STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; TIME; URINALYSIS; URINARY TRACT DISEASE; URINE CYTOLOGY; VOLUNTEER;

ADULT; AGED; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 25844526464     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin, 1998,48:269-284.
2. John ston B, Morales A, Emerson L, et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol, 1997, 158: 2098-2101.
3. Wiener H G, Mian C H, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer. J Urol, 1998,159:1876-1880.
4. Giella J G, Ring K, Olsson CA, et al. The predictive value of flow cytometry and urinary cytology in the follow up of patients with transitional cell carcinoma of the bladder. J Urol, 1992, 148: 293-296.
5. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res, 1998,4:2511-2520.
6. Johnston B, Morales A, Emerson L, et al. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol, 1997, 158: 2098-2101.
7. Giannopoulos A, Manousakas T, Gounari A, et al. Comparative evaluation of the diagnostic performance of the BTAstat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol, 2001, 166:488-489.
8. Soloway MS, Briggman JV, Carpinito CA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract follow surgical treatment. J Urol, 1996, 156:363-367.
9. Carpinito GA, Stadler WM, Briggman JV, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol, 1996, 156:1280-1285.
10. Hughes JH, Katz RLdriguez, Villanueva J, et al. Urinary nuclear matrix protein22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional cell carcinoma of the bladdr. Diagn Cytopathol, 1999, 20:285-291.
11. Menendez V, Filella X, Alcover JA, et al. Usefulness of urinary nuclear matrix protein22 (NMP22) as a marker for transitional cell carcinoma of the bladder. Anticancer Res, 2000, 20:1169-1174.
12. Sanchez Carbayo M, Herreo E, Megias J, et al. Evaluation of nuclear matrix protein 22 as a tumor marker in the detection of transitional cell carcinoma of the bladder. Br J Urol, 1999, 84: 706-710.
13. Zippen C, Pandrangi L, Agarwal A. NMP22 is a sensitive cost - effective test in patients at risk for bladder cancer. J Urol, 1999, 161: 62-67.
14. Lokeshwar VB, Obek C, Soloway MS, et al. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res, 1997, 57:773-777.
15. Pham HT, Block NL, Lokeshawar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res, 1997, 57:778-783.
16. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecular survivin and recurrence of bladder cancer. N Engl J Med, 1999, 341:452-453.
17. Sharp JD, Hausladen HA, Maher MG, et al. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci, 2002, 7: 36-41.
18. Naot D, Sionov RV, Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res, 1997, 71: 241-319.
19. Screaton GR, Bell MV, Jackson DG, et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci, 1992, 89:12160-12164.
20. Ross JS, del Rosario AD, Bui HX, et al. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. MedPathol, 1996, 9:854-860.
21. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol, 1996, 149:873-882.
22. Toma V, Hauri D, Schmid U, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol, 1999, 155:1427-1432.
23. Woodman AC, Goodison S, Drake M, et al. Non-invasive diagnosis of bladder carcinoma by enzyme linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia. Clin Cancer Res, 2000, 6: 2381-2392.
24. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med, 1971, 285:1182-1186.
25. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res, 1997, 57:5281-5285.